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ABSTRACT   Brain-derived neurotrophic factor (BDNF) is necessary for the development, 
growth, and maintenance of nerve cells. BDNF is expressed in the dorsal root ganglion (DRG); 
binds to the Tropomyosin receptor kinasa B (TrkB) receptor, which has a tyrosine kinase 
domain, in the spinal cord; and plays an important role as a pain modulator. BDNF expression 
is increased in various types of pain, including acute pain, neuropathic pain, and cancer pain. 
Activation of the BDNF–TrkB pathway transmits pain information. In order to inhibit the BDNF–
TrkB pathway, by sequestering BDNF, we constructed a cDNA expression plasmid encoding 
the extracellular region of rat TrkB fused to enhanced green fluorescent protein (EGFP). When 
the expression plasmid vector was administered to rat models of neuropathic pain, induced 
by spinal nerve ligation, statistically significant relief of pain was observed in terms of a 50% 
paw-withdrawal threshold using the von Frey test. The expression of TrkB-EGFP mRNA was 
detected in L5 lumbar vertebral nerves by quantitative reverse transcriptase polymerase chain 
reaction. To verify the pain-suppressive effect of the expression vector, truncated TrkB protein, 
without EGFP, was purified, and administered to pain model rats. A statistically significant 
suppressive effect of the truncated TrkB protein on neuropathic pain was observed 2 days after 
administration. The pain-suppressive effect of the truncated TrkB protein was more effective 
than that of the TrkB-Fc chimera protein and lasted longer than that of the TrkB antagonist 
ANA-12. Our results suggested that the truncated TrkB cDNA expression vector and truncated 
TrkB protein could be used as molecular targeted drugs in patients with neuropathic pain.
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〈Regular Article〉
INTRODUCTION
   Various factors participate in the perception 
of neuropathic pain; these include neurotropic 
factors１－３）. Brain-derived neurotrophic factor 
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region of rat TrkB (from methionine 1 to histidine 
429) fused with EGFP, in our previous study13）. 
After the plasmid was transfected in HEK293 cells, 
we confirmed that the eTrkB-EGFP protein was 
secreted from the transfected cells, and that the 
protein could bind to BDNF, by using a pull-down 
assay implementing S-protein agarose beads, as well 
as by western blotting13）. Administration of these 
vectors exerted an analgesic effect in rat models of 
cancerous osteocopic pain13）. In the present study, 
we showed that administration of the vector can 
also suppress neuropathic pain in a rat model. To 
verify the function of the gene products from the 
vector, we purified the protein composed of only the 
extracellular domain of TrkB (hereinafter referred 
to as “eTrkB”) and showed that administration 
of the eTrkB protein can suppress the pain in 
neuropathic pain model rats. The vector and protein 
might be considered as molecular targeted drugs for 
intractable chronic pain, including neuropathic pain.
MATERIALS AND METHODS
Materials
   ANA-12 (N-[2-[[(hexahydro-2-oxo-1H-azepin-
3-yl)amino]carbonyl]phenyl]-benzo [b] thiophene-
2-carboxamide), which is an antagonist of TrkB, 
was purchased from Sigma–Aldrich (SML0209; St 
Louis, MO, USA). The TrkB-Fc chimera protein 
was purchased from R&D systems (688-TK-100; 
Minneapolis, MN, USA).
Construction of the eTrkB gene expression vectors
   As a vector for DNA administration into rats, 
pCMVscript-eTrkB-EGFP, encoding only the 
extracellular domain region of TrkB fused to 
enhanced green fluorescent protein (EGFP), was 
constructed in previous our study13）. Briefly, we 
extracted mRNA from the brain tissue of rats, and 
synthesized cDNA by reverse transcription. We 
amplified the eTrkB cDNA region, encoding the 
extracellular domain of TkrB, by PCR, using the FW 
(BDNF), a member of the neurotropic factor family, 
is necessary for nervous system development, 
growth, and maintenance４）, and plays an important 
role as a pain modulator.  In the peripheral 
nervous system, BDNF is expressed in the dorsal 
root ganglion (DRG) under painful conditions, 
from which it is secreted, and then binds to the 
Tropomyosin receptor kinasa B (TrkB) receptor, 
a member of the tropomyosin kinase receptor 
family, on the posterior horn of the spinal cord; 
this modulates pain transduction from peripheral 
nociceptors５－７）.
   The precise mechanism by which BDNF transmits 
pain information remains unclear. When BDNF 
binds to TrkB, the activation of the BDNF–TrkB 
pathway can evoke membrane depolarization 
through rapid activation of the sodium ion channel 
NaV1.9, which has been linked to pain in humans８）. 
The tyrosine kinase domain of TrkB is activated, 
leading to activation of phosphoinositide 3-kinase 
(PI3K), extracellular signal-regulated kinase (ERK), 
and phosphoinositide phospholipase C (PLCγ)９）. 
In previous reports, neuropathic pain was increased 
by administration of BDNF to mice７）,  and 
neuropathic pain was decreased in rats and mice by 
inhibition of the BDNF–TrkB pathway７，10）.
   Various treatments are provided for patients with 
neuropathic pain; however, some treatments are not 
effective, and neuralgia often persists11）. Because 
there is few effective drugs, the use of strong opioids 
has increased, which may have contributed to the 
recent opioid crisis12）. Therefore, we have focused 
on developing new therapeutic drugs to decrease the 
usage of opioids. If BDNF, a modulator of the pain, 
could be restricted in patients with intractable pain, 
the BDNF–TrkB pathway would be inhibited, and 
neuropathic pain might be improved.
   In a previous study, in order to inhibit the BDNF–
TrkB pathway by sequestering BDNF, we had 
previously constructed a cDNA expression plasmid, 
pCMVscript-eTrkB-EGFP, encoding an extracellular 
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primer (5'-GGA TCC GCC ATG TCG CCC TGG 
CCG AGG TG-3', including a BamHI restriction 
enzyme site) that targets the translation initiation 
region and the RV primer (5'-GAA TTC ATG CTC 
CCG ATT GGT TTG GTC-3', including an EcoRI 
restriction enzyme site) that targets the region 
upstream of the transmembrane region. The PCR 
product was cloned into pBluesript KS at the EcoRV 
site, and was confirmed by sequencing analysis. The 
eTrkB cDNA was digested by BamHI and EcoRI, 
and inserted between the BamHI and EcoRI sites of 
the pCMVscript-EGFP vector. Sequencing analysis 
confirmed a fusion gene encoding eTrkB, EGFP, a 
FLAG-tag, and an S-tag, in-frame. This plasmid, 
pCMVscript-eTrkB-EGFP, was administered to 
neuropathic pain model rats.
   As a vector for producing and purifying proteins 
for protein administration into rats, the plasmid 
pCMVscript-eTrkB encoding the extracellular 
domain region of TrkB, without EGFP, was 
constructed. Briefly, the truncated extracellular 
domain region of rat TrkB, eTrkB, was produced 
by DNA synthesis (TaKaRa-Bio, Shiga, Japan); it 
encoded 425 amino acids of TrkB, from the first 
methionine to threonine 425. The 3' end of the 
cDNA was fused to a FLAG-tag, S-Tag, and His-
tag, in-frame, and was cloned into the pCMVscript 
plasmid. 
Purification of eTrkB protein and BDNF-binding 
assay
   pCMVscript-eTrkB (a vector for protein 
purification) was transfected into HEK293 cells 
by using Lipofectamine2000 (Thermo Fisher 
Scientific, Tokyo, Japan). The medium was changed 
to serum-free OPTI-MEM medium (Thermo Fisher 
Scientific) on the next day, and the culture medium 
(1 L) was collected at 72 h after transfection. 
Protease inhibitor (10 μl; P1860, Sigma), 500 ng 
of BDNF protein (ab9794, mature type; Abcam, 
Cambridge, UK) and S-protein agarose beads (50 
μl; Novagen, Madison, WI, USA) were added to 1 
ml of the culture medium; the samples were mixed 
for 2 h at 4℃ , and the solution was centrifuged at 
5,000 rpm for 3 min. After washing, the S-protein 
agarose complex was subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and blotted onto a polyvinylidene fluoride 
(PVDF) membrane. Anti-FLAG mouse antibody 
(F3165, Sigma) and anti-TrkB mouse antibody 
(#4603; Cell Signaling Technology, Danvers, 
MA, USA), for detecting truncated eTrkB protein 
fused with Tag peptides, and anti-BDNF rabbit 
antibody (ab9793; Abcam), for detecting BDNF, 
were added. Membranes were then incubated with 
anti-mouse IgG-HRP antibody (CST; #7076) and 
Western Lightning Plus-ECL (PerkinElmer Japan, 
Kanagawa, Japan), and chemiluminescence was 
detected using the LAS-1000 (FUJIFILM). After 
we confirmed that the eTrkB protein retained the 
BDNF-binding activity, the eTrkB protein was 
purified from culture medium (1 L) using Ni-NTA 
column (QIAGEN, Hilden, Germany), and eluted 
with 250 mM imidazole (pH 8.0). 
Animal treatment
   All experiments in this study were performed 
according to the protocol  approved by the 
Institutional Animal Care and Use Committee of 
Kawasaki Medical School (approval number 15-
0111). 
   Wister rats (7 weeks old) were subjected to 
a pain evaluation using von Frey filaments, as 
described below (day 0). Thereafter, neuropathic 
pain model rats were generated. After incising the 
back under general anesthesia with sevoflurane, the 
L6 transverse process was identified and removed, 
and the left L5 lumbar nerve was ligated by silk 
thread of 5-0 at a position more peripheral than the 
posterior root ganglion14）. 
   One week later (day 7), rats were again subjected 
to pain evaluation with von Frey filaments. A dorsal 
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skin incision was made from L3 to L6 under general 
anesthesia with sevoflurane; the lumbar level was 
identified from the vertebral spinous process and 
pelvis. A 23-G needle was inserted into the spinal 
cord’s subarachnoid space from the muscular fasciae 
of L5/6, and a sterilized catheter (polyethylene tube, 
inner diameter: 0.2 mm, outer diameter: 0.5 mm) 
for administration of treatment was inserted into the 
spinal cord’s subarachnoid space through the needle. 
   For DNA administration, the vector DNA was 
pretreated with transfection reagent GenomONE 
(HVJ Envelope VECTOR KIT; Ishihara Sangyo 
Kaisha, Ltd., Osaka, Japan), and the vector DNA 
mixture (1 μg/μL, 10 μL) was administered 
through the catheter. 
   For administration of protein and other reagents, 
purified eTrkB protein (100 ng/3 μL), heat-
inactivated eTrkB protein (95℃ , 4 min) (100 ng/3 
μL), ANA-12 (100 ng/5 μL), TrkB-Fc protein 
(100 ng/5 μL), and TrkB-Fc protein (1 μg/5 μL) 
were administered through the catheter. Saline 
(20 μL) was added through the catheter after 
the dose administration. Rats were subjected to 
pain evaluations for 1 week afterwards, and then 
sacrificed under general anesthesia with sevoflurane.
Pain evaluation
   For pain evaluation, the von Frey test was 
performed using von Frey filaments (Tactile Test 
Aesthesio, Muromachi Kikai Co., Tokyo, Japan), 
and the 50% paw withdrawal threshold (PWT) 
was calculated as the pain threshold15）. The pain 
evaluation test was performed on days 0, 2, 5, 7, 
9, 12, and 14 (day 0 indicates the von Frey test 
performed immediately before the nerve ligation 
operation, and day 7 indicates the test immediately 
before treatment administration). As a pain 
evaluation test after administration of ANA-12, the 
von Frey test was performed at 4 h (day 7.5) and at 
24 h (day 8) after ANA-12 administration.  
Real-time PCR
   After the pain threshold was evaluated at day 
14, rats were sacrificed, and L5 spinal cords were 
resected under general anesthesia with sevoflurane. 
RNA was extracted with an RNeasy Lipid Tissue 
Mini Kit (Qiagen), treated with DNase I, and 
reverse-transcribed into cDNA using a Ready-to-Go 
T-primed First-Stand kit (Amersham Biosciences, 
Little Chalfont, UK). To verify the mRNA expressed 
from the plasmid vector administered to the rats, 
eTrkB-EGFP mRNA and internal control RPL-27 
(ribosomal protein L27) mRNA were analyzed by 
quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) on a StepOne Plus Real-Time 
PCR System (Applied Biosystems, Foster City, CA, 
USA) with the RPL-27 FW-primer 5'-GAA TTG 
ACC GCT ATC CCA GA-3' and RV-primer 5'-TCG 
CTC AAA CTT GAC CT-3' (product size: 230 bp), 
and GFP FW-primer 5'-CGA CAA CCA CTA CCT 
GAG-3' and RV-primer 5'-GAA TTT AGC GGT TT-
3' (product size: 178 bp).
Statistical analysis
   Statistical analyses were performed using 
GraphPad Prism7, jmp13, and SPSS. The von Frey 
test results were analyzed using the Wilcoxon rank-
sum test, which was corrected using the Bonferroni 
method for days 7, 9, 12, and 14. Gene expression 
results based on qRT-PCR were evaluated using the 
trend test (SPSS Ver. 18). A value of p < 0.05 was 
considered statistically significant.
RESULTS
Effect of eTrkB expression vector on neuropathic 
pain
   In the present study, we administered this 
expression vector to a rat model of neuropathic pain. 
First, we generated a rat model of neuropathic pain 
by spinal nerve ligation (day 0)14）, and divided the 
rats into two groups. One week later, the 50% PWT 
was measured using the von Frey test in rats in both 
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Fig. 1. Effect of eTrkB-EGFP expression vector on neuropathic pain. 
Neuropathic pain was induced in rats by spinal nerve ligation on day 0, and the 50% paw withdrawal threshold (PWT) was 
evaluated using the von Frey test on days 0, 2, 5, 7, 9, 12, and 14. Rats were administered pCMVscript-eTrkB-EGFP vector (n = 
6) or empty vector pCMVscript-EGFP (n = 5) on day 7, after conﬁrming that there was no signiﬁcant difference in the 50% PWT 
between the two groups. On day 9, statistically signiﬁcant relief of pain was observed in the eTrkB vector-administered group (*, 
p = 0.032).
groups, immediately before DNA administration 
(day 7). After confirming that there was no 
difference in the 50% PWT between the two groups, 
the rats were administered the pCMVscript-eTrkB-
EGFP vector  or the empty vector pCMVscript-
EGFP (day 7). The pain threshold was tested on 
days 0, 2, 5, 7, 9, 12, and 14.
   The effect of eTrkB vector administration on 
neuropathic pain is shown in Fig. 1. On day 7 
(before vector administration), the 50% PWT was 
2.34 vs. 2.85 in the eTrkB vector group (n = 6) 
vs. empty vector group (n = 5), respectively (p 
= 1.00), suggesting that there was no significant 
difference between the two groups prior to vector 
administration. On day 9 (2 days after DNA 
administration), the 50% PWT was 9.22 vs. 1.86 
(eTrkB vector group vs. empty vector group, p = 
0.032), suggesting statistically significant alleviation 
of pain in the eTrkB vector-administered group. 
On day 12 (5 days after DNA administration), the 
50% PWT was 5.69 vs 4.72 (eTrkB vector group vs. 
empty vector group, p = 1.00), suggesting that there 
was no significant difference.
Confirmation of the eTrkB gene expressed from the 
expression vector
   L5 lumbar vertebral nerves were resected from 
the neuropathic pain model rats before and after the 
vector administration (days 7, 9, 12, and 14, each 
n = 4); mRNA was extracted and analyzed by qRT-
PCR using EGFP primers and internal control gene 
primers (Fig. 2). The mRNA of the eTrkB-EGFP 
gene was not detected before vector administration 
(day 7), but was detected strongly at 2 days after 
vector administration (day 9). The expression of the 
eTrkB-EGFP gene was significantly decreased at 
5 and 7 days after administration (days 12 and 14) 
(Trend test, p = 0.03) (Fig. 2).
Effect of eTrkB protein on neuropathic pain
   To verify the pain-suppressive effect of the eTrkB-
EGFP expression vector, we aimed to purify the 
eTrkB protein, lacking EGFP, and to administer 
it to neuropathic pain model rats. As a vector 
for producing the eTrkB protein, a plasmid was 
constructed that encoded the TrkB extracellular 
region (from the 1st to 425th amino acid), fused 
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Fig. 2. Conﬁrmation of the eTrkB-EGFP gene expressed from the expression vector. 
Spinal cords were dissected from rats before and after eTrkB-EGFP vector administration (days 7, 9, 12, and 14, each n = 
4), mRNA was extracted and reverse-transcribed. The eTrkB-EGFP mRNA expression was analyzed by quantitative reverse 
transcriptase polymerase chain reaction with EGFP primers, normalizing against the expression of the internal control RPL-27 
mRNA. The mRNA of the eTrkB-EGFP gene was detected strongly 2 days after vector administration (day 9). RPL-27, ribosomal 
protein L27; *, Trend test p = 0.03.
Fig. 3. BDNF-binding activity of eTrkB protein.
A plasmid encoding the extracellular domain of TrkB, fused in-frame to FLAG-Tag, S-Tag, and His-Tag (without EGFP), was 
constructed, and transfected into human HEK293 cells. (A) The eTrkB protein secreted into the culture medium was analyzed by 
western blotting using anti-TrkB and anti-FLAG antibodies. Lane 1, empty vector; lane 2, pCMVscript-eTrkB. (B) The plasmid 
was transfected to HEK293 cells, BDNF was added to the culture medium collected from the culture dishes. The BDNF-binding 
activity of eTrkB protein secreted into culture medium was examined using a pull-down assay with S-protein agarose beads and 
western blotting with the anti-BDNF antibody. Lane1, empty vector; lane 2, pCMVscript-eTrkB.
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Fig. 4. Effect of eTrkB protein on neuropathic pain.
(A) The effect of eTrkB protein administration on neuropathic pain model rats was evaluated in the eTrkB protein administration 
group (n = 9) and control group (saline administration, n = 6). The protein (100 ng) was administered on day 7 after evaluation 
by the von Frey test. On day 9, a statistically signiﬁcant suppressive effect of eTrkB protein on neuropathic pain was observed 
(*, p = 0.007). (B) The effect of heat-inactivated eTrkB protein administration on pain model rats was evaluated in the protein 
administration group (n = 9) and control group (saline administration, n = 6). The heated protein (100 ng) was administered on 
day 7 after evaluation using the von Frey test.
to a FLAG-Tag, S-Tag, and His-Tag in frame in 
pCMVscript plasmid. After transfection of the 
plasmid into human HEK293 cells, the western 
blotting and pull-down assay showed that the eTrkB 
protein was secreted into the culture medium and 
bound to BDNF (Fig. 3). Then, the protein was 
purified from the culture medium, and administered 
to rat models of neuropathic pain, similar to the 
vector administration experiment. 
   The effect  of  protein adminis t ra t ion on 
neuropathic pain was evaluated in the eTrkB protein 
administration group (n = 9) and the control group 
(saline administration) (n = 6) (Fig. 4A). On day 7 
(before protein administration), the 50% PWT was 
1.56 vs. 1.01 (eTrkB protein group versus control 
group, p = 1.00), suggesting that there was no 
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significant difference before the administration. On 
day 9 (2 days after administration), the 50% PWT 
was 10.73 vs. 1.19 (eTrkB protein group vs. control 
group, p = 0.007), suggesting that the eTrkB protein 
had a significant suppressive effect on neuropathic 
pain. On day 12 (5 days after administration), the 
50% PWT was 4.78 vs. 1.32 (eTrkB protein group 
vs. control group, p = 0.179), suggesting that 
there was a trend for a suppressive effect in the 
administration group.
Confirmation of the suppressive effect of eTrkB by 
heat-inactivation
   To verify the suppressive effect of eTrkB protein 
on neuropathic pain, the eTrkB protein was heated 
at 95℃ for 4 min. On day 7, we administered the 
heat-denatured protein to the pain model rats, and 
evaluated their pain threshold (n = 9). On day 9, 
the heat-denatured eTrkB administration group 
did not show any significant difference from the 
control group (Fig. 4B). This result confirmed the 
suppressive effect of eTrkB protein on neuropathic 
pain. 
Effect of TrkB-Fc protein on neuropathic pain
   It has been reported that a fusion protein of human 
TrkB and immunoglobulin, TrkB-Fc, showed a 
suppressive effect on pain in a sciatic nerve ligation 
model mouse7). Therefore, we evaluated the effect 
of TrkB-Fc protein on model rats of neuropathic pain 
induced by spinal nerve ligation. After generating 
pain model rats, an equal amount of TrkB-Fc protein 
(100 ng/5 μl) was administered on day 7 (n = 6), 
and their pain threshold was evaluated. However, 
there was no significant difference between the 
TrkB-Fc administered group and the control group 
(Fig. 5A). We then administered a 10-fold increased 
amount (1 μg/5μl), and confirmed a suppressive 
effect of the TrkB-Fc protein on neuropathic pain in 
the rat model (Fig. 5B). 
Effect of ANA-12 on neuropathic pain
   ANA-12  is  known to inhibit  the BDNF–
TrkB pathway as an antagonist of TrkB21）. We 
administered ANA-12 (100 ng/5 μl) to pain model 
rats on day 7 after spinal nerve ligation (n = 7). In 
comparison with the control group, there was no 
significant difference prior to administration: 0.74 
vs. 0.78 (ANA-12 group vs. control group, p = 
1.00) (Fig. 6). At 4 h after ANA-12 administration 
(day 7.5), a significant difference was observed; 
the 50% PWT was 11.83 vs. 1.01 (ANA-12 group 
vs. control group, p = 0.013). On the next day (day 
8), a tendency for the pain-suppressive effect was 
observed in the ANA-12 administration group, 
but there was no statistically significant difference 
between the groups; the 50% PWT was 3.47 vs. 1.19 
(ANA-12 group vs. control group, p = 0.070). It was 
1.60 vs. 1.32 (ANA-12 group versus control group, 
p = 0.88) at 2 days after the administration (day 9). 
DISCUSSION
   BDNF has been reported to participate in 
the experience of various types of pain１，16－18） 
and its expression is increased in various pain 
models, including acute pain and neuropathic pain 
models１，16，17）, and in a tibia cancer pain model18）. 
Its specific receptor is TrkB19）, and BDNF acts as 
a modulator of pain by binding to TrkB20）. Some 
molecules in the BDNF–TrkB signal pathway are 
considered to be targets for analgesic drugs.
   In the present study, we showed an improvement 
in the pain threshold after administration of a 
TrkB cDNA expression vector that encodes only 
an extracellular region of TrkB (eTrkB) into the 
subarachnoid space of the spinal cord in rat models 
of neuropathic pain induced by spinal nerve ligation. 
The mRNA expression of TrkB-EGFP was observed 
2 days after administration, by qRT-PCR. This 
result supports the results of an evaluation by the 
von Frey test in which the pain threshold showed 
statistically significant improvement 2 days after the 
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vector administration. In our previous study, using 
rat models of cancerous osteocopic pain, we showed 
improvement in the pain threshold by administering 
this vector into the subarachnoid space of the spinal 
cord of cancer pain model rats13）, and confirmed 
that TrkB-EGFP was expressed from the vector 
in the posterior horn of the spinal cord, using 
immunohistochemical analysis.
   In clinical practice, administrating an expression 
vector into the subarachnoid space of the spinal 
cord may pose risks, such as neuropathy. Therefore, 
we produced the eTrkB protein that was composed 
of only an extracellular region of TrkB, and 
administered it into the subarachnoid space of the 
spinal cords of neuropathic pain model rats. The 
pain threshold was improved by eTrkB protein 
administration. In comparison, no pain alleviation 
was observed when the heat-inactivated eTrkB 
protein was administered in the same manner. These 
results suggested that the eTrkB protein functions 
Fig. 5. Effect of TrkB-Fc protein on neuropathic pain.
(A) The effect of TrkB-Fc chimeric protein administration on neuropathic pain model rats was evaluated in the protein 
administration group (n = 6) and control group (saline administration, n = 6). The protein (100 ng) was administered on day 7 
after evaluation using the von Frey test. (B) TrkB-Fc chimeric protein (1 μg) was administered in a model rat of neuropathic 
pain, induced by spinal nerve ligation.
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in improving the pain threshold. Furthermore, 
the results of eTrkB protein administration might 
explain the mechanism underlying the pain-
suppressive effect of the eTrkB expression vector in 
neuropathic pain model rats.  
   Yajima et al. reported that thermal hyperalgesia 
and tactile allodynia of model mice subjected to 
sciatic nerve ligation were suppressed by repeated 
intrathecal injection of a human TrkB-Fc chimera 
protein, which sequesters BDNF７）. Here, we 
evaluated the effect of TrkB-Fc protein in a rat 
model of neuropathic pain induced by spinal nerve 
ligation as a comparative experiment. When we 
administered a single dose of a 10-fold excess 
amount of TrkB-Fc (1 μg), as compared with the 
eTrkB protein amount (100 ng), a suppressive effect 
of TrkB-Fc protein was observed in a neuropathic 
pain model rats. However, the suppressive effect 
was not observed with a single dose of TrkB-Fc 
(100 ng). This may indicate that the binding activity 
of human TrkB (TrkB-Fc) and rat TrkB (eTrkB), to 
BDNF differ. Repeated injection of TrkB-Fc protein 
(100 ng) may be effective in pain model rats. Our 
results showed that a single administration of eTrkB 
protein has a suppressive effect on pain, even when 
using a smaller amount than that of TrkB-Fc protein. 
   ANA-12 is small molecule that antagonizes 
TrkB, inhibits processes downstream of TrkB, and 
prevents activation of the receptor by BDNF21）. 
Some studies have reported that ANA-12 improved 
depression22，23）. Improvement in the pain threshold 
by ANA-12 has not been reported previously. A 
suppressive effect of ANA-12 on pain model rats 
was observed 4 h after administration. However, 
on the next day (day 8), although there was a 
tendency for a pain-suppressive effect, there was 
no statistically significant difference. Because there 
was an improvement in the pain threshold 2 days 
after eTrkB protein administration (day 9), a single 
dose of eTrkB protein into the subarachnoid space 
of the spinal cord appears to be long-acting, as 
compared with ANA-12. 
   In conclusion, in neuropathic pain model rats, 
the pain threshold was improved by administration 
of a TrkB extracellular domain-encoding cDNA 
expression vector and of eTrkB protein. This 
protein had an analgesic effect that was higher than 
that of TrkB-Fc protein of the same amount, and 
Fig. 6. Effect of ANA-12 on neuropathic pain.
The effect of ANA-12 administration on neuropathic pain model rats was evaluated in the ANA-12 administration group (n = 7) 
and control group (saline administration, n = 6). ANA-12 (100 ng) was administered on day 7 after evaluation using the von Frey 
test. For evaluation of pain after administration of ANA-12, the von Frey test was performed at 4 h (day 7.5) and at 24 h (day 8) 
after administration of the dose. *, p = 0.013.
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persisted for a longer time than that of ANA-12. 
Furthermore, the eTrkB vector was shown to have 
a pain-suppressive effect in a cancer pain model in 
our previous report. The eTrkB expression vector 
and the protein might be considered for use as new 
therapeutic reagents for intractable chronic pain, 
including neuropathic pain and cancer pain. In 
the future, clinical application, we intend to push 
forward a study including dosage methods. 
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